Opko Health, Inc. s in-depth stock price analysis indicates that the stock price has dropped -21.57% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -9.87% . Looking at the past 52 week period, the stock price is up at 4.18% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Opko Health, Inc. has a negative value of -10.49 compared to overall market performance. Opko Health, Inc. (NASDAQ:OPK) has tumbled 4.53% during the past week and has dropped 10.16% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 5.3%. Opko Health, Inc. (NASDAQ:OPK) has underperformed the index by 11.77% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Opko Health, Inc. (NASDAQ:OPK) : On Friday heightened volatility was witnessed in Opko Health, Inc. (NASDAQ:OPK) which led to swings in the share price. The stock opened for trading at $8.17 and hit $8.26 on the upside , eventually ending the session at $8.22, with a gain of 1.48% or 0.12 points. The heightened volatility saw the trading volume jump to 3,616,400 shares. The 52-week high of the share price is $12.15 and the company has a market cap of $4,583 million. The 52-week low of the share price is at $7.64 .
Opko Health Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.03 EPS for the quarter. Analyst had a consensus estimate of $-0.03. The company had revenue of $298.00 million for the quarter, compared to analysts expectations of $322.03 million. The companys revenue was up 108.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS.
Company has reported several Insider transactions to the SEC, on Feb 10, 2017, Gamma Investments Trust Frost (CEO) purchased 10,000 shares at 8.06 per share price.On Feb 9, 2017, Steven D Rubin (Executive VP-Administration) purchased 2,000 shares at 8.11 per share price.On May 17, 2016, Robert A Baron (director) sold 37,500 shares at 9.83 per share price.
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.